The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2

• Published in: The Korean journal of internal medicine 2021, 36(3), , pp.544-556
• Main Authors: Han, Sung Yong, Woo, Hyun Young, Heo, Jeong, Park, Sang Gyu, Pyeon, Sung Ik, Park, Young Joo, Kim, Dong Uk, Kim, Gwang Ha, Kim, Hyung Hoi, Song, Geun Am, Cho, Mong
• Format: Article
• Language: English
• Subjects: Antiviral Agents - adverse effects; carcinoma, hepatocellular; Carcinoma, Hepatocellular - drug therapy; Drug Therapy, Combination; Genotype; Hepacivirus - genetics; hepatitis c, chronic; Hepatitis C, Chronic - diagnosis; Hepatitis C, Chronic - drug therapy; Humans; Liver Cirrhosis - diagnosis; Liver Cirrhosis - drug therapy; Liver Neoplasms - drug therapy; Neoplasm Recurrence, Local; Original; rapid virological response; Ribavirin - adverse effects; sofosbuvir; Sofosbuvir - adverse effects; sustained virological response; Treatment Outcome; 내과학
• ISSN: 1226-3303; 2005-6648; 2005-6648
• DOI: 10.3904/KJIM.2018.329

Real-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and safety of SOF/RBV in Korean patients with HCV GT2 infection and clinical factors predicting sustained virological response 12 weeks (SVR12) after the end of SOF/RBV treatment. A total of 181 patients with HCV GT2 with/without cirrhosis were treated with SOF/RBV for 16/12 weeks. Rapid virological response (RVR) was defined as non-detectable HCV RNA at 4 weeks. The RVR rate was 80.7% (146/181), the end of treatment response rate was 97.8% (177/181) and the SVR12 rate was 92.8% (168/181). Of eight patients with relapse, four did not achieve RVR. Three patients had a history of hepatocellular carcinoma (HCC). Multivariable analysis showed that RVR (p = 0.015) and no previous history of HCC (p = 0.007) were associated with SVR12. Factors significantly contributing to RVR included cirrhosis, creatinine concentration, and pre-treatment HCV RNA level. SVR12 rate was significantly higher in RVR (+) than RVR (-) patients (95.2% vs. 82.9%, p = 0.011) and also significantly higher in patients without than with a history of HCC (94.1% vs. 72.7%, p = 0.008). During treatment, 80/181 patients (44.2%) experienced mild to moderate adverse events, with 32 (17.7%) requiring RBV dose reductions due to anemia. SOF/RBV treatment was effective and tolerable in HCV GT2 patients. RVR and no previous history of HCC were positive predictors of SVR12.